< Arab Finance - News - Rameda's shareholders okay capital increase
Count Down to relaunch

Rameda's shareholders okay capital increase

Rameda's shareholders okay capital increase

ArabFinance: Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents’ (Rameda) (RMDA) extraordinary general assembly ratified issued capital increase by EGP 57.850 million, according to the company’s May 20th statement.

The company will increase capital to EGP 250 million from EGP 192.150 million.

The capital increase will be through the distribution of 0.30 free share for everyone held, an equivalent of 768.6 million shares.

Following the increase, Rameda’s capital will be amounting to EGP 250 million distributed on one billion shares at par value of EGP 0.25 per each.

Ramed posted a consolidated net profit before minority interest of EGP 30.009 million in quarter one (Q1) 2021.

Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.

#Related keywords


Recommended Stocks

13 Jun 2022
Delta Sugar SUGR

All rights reserved to Arab Finance 2020 ©

Back to top